Mergers & Acquisitions
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Track global pharma M&A deals, divestitures, and partnerships. Gain critical intelligence for strategic investment and business development in life sciences.
Showing 1–12 of 62 articles
Otsuka kidney drug data and Pfizer AI deal: Biopharma deal tracker
Otsuka released Phase 3 data for Voyxact in IgA nephropathy, showing slowed kidney function decline but leaving room for competitors. Pfizer struck an AI deal, signaling increased automation in drug development.
Kairos Pharma Highlights CL-741 Acquisition and 2026 Clinical Milestones: A Strategic Analysis for Pharma Decision-Makers
Kairos Pharma has signed a term sheet to acquire CL-741, a clinical-stage oncology asset, and outlined key 2026 milestones including a Phase 1 trial initiation. This article provides a competitive benchmarking analysis for pharma strategists and investors, covering the deal's rationale, pipeline impact, and what to watch next.
China: The Innovation Factor – Implications for Pharma BD and Investors
China has emerged as a global innovation powerhouse, now leading in 37 of 44 critical technologies. This article examines what this means for pharmaceutical deal-making, investment decisions, and competitive strategy for BD teams and executives.
Utah Medical Board Scolded for Going Rogue with AI Criticism: Deal Implications for Pharma
The Utah Medical Board was publicly scolded for its rogue criticism of Doctronic's AI prescribing pilot. This analysis breaks down the regulatory clash, implications for pharma deal teams, and what to watch next.
SGS Expands Bioanalytical Testing Capabilities in North America with Acquisition of CMIC, INC.
SGS has acquired CMIC, INC., a Chicago-based bioanalytical testing firm, expanding its North American capabilities. The move follows the Keystone Bioanalytical acquisition and signals SGS's commitment to end-to-end drug development lifecycle testing.
Mercury Acquires King Courier to Grow Bay Area Logistics: Deal Intelligence for Pharma Teams
Mercury, a global healthcare and life sciences logistics provider, has acquired King Courier, a San Francisco-based logistics company serving Northern California for decades. The deal expands Mercury's operations in one of the nation's largest biotech and healthcare hubs.
Best Biotech News Sources: How Legend Biotech Emerged as a Rare Market Winner
Legend Biotech shares soared over 40% after disclosing early in vivo CAR-T data in Non-Hodgkin's lymphoma. This analysis explains the development, implications for pharma teams, and key milestones to track.
Fierce Biotech Week 2026: Key Insights and Highlights
Fierce Biotech Week 2026 delivered critical updates on gene therapy, mRNA platforms, and regulatory shifts from the FDA and EMA. This article provides key takeaways, implications for BD teams and investors, and a FAQ section.
House bill aims to crack down on China biotech deals
Structured plan for House bill aims to crack down on China biotech deals
ASCO Summit: Ivonescimab's China Lung Data Shows Promise, But Global Validation Remains Key
Summit Therapeutics' ivonescimab demonstrated a significant survival benefit in a Chinese lung cancer trial presented at ASCO, yet analysts caution that replicating these results in a broader, global population is crucial for its market potential against established therapies like Keytruda.
Vir Biotechnology Stock: Board Reshuffle and Governance Votes Post-AGM
Vir Biotechnology is undergoing significant leadership changes post-AGM, with a board reshuffle and key governance votes set to influence its strategic direction. Investors and pharmaceutical BD teams should monitor these developments for potential shifts in clinical trial focus and market positioning.
STAT+ R&D Performance Ranking: Insights for Pharma Companies
Structured plan for STAT+ R&D Performance Ranking: Insights for Pharma Companies